Trial Profile

A Phase I/II Study of Evaluating the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Curative Effect of Dose Escalation and Extension for Single Drug TJ004309 and Toripalimab Combine Treatment for Advanced Solid Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Uliledlimab (Primary)
Indications Lung cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; Biomarker
Sponsors I-MAB Biopharma; TJ Biopharma

22 May 2025 Planned End Date changed from 30 Apr 2025 to 30 Dec 2025.
22 May 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Dec 2025.
24 Apr 2025 Planned End Date changed from 1 Dec 2024 to 30 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com